Brain-computer interface startup Gestala has secured RMB 570 million, approximately US$84 million, in two funding rounds within six months of its launch. The company is pioneering a non-invasive approach using ultrasound technology to read from and write to the brain. This significant investment highlights growing confidence in alternatives to traditional implantable BCI devices and signals Gestala's rapid emergence.
A Rapid Ascent in the BCI Landscape
Since its January 2026 inception, Gestala has shown remarkable speed, securing a RMB 150 million angel round in March followed by a RMB 420 million Angel+ round in July. The company quickly established dual headquarters in Chengdu and Shanghai and attracted senior talent from industry leaders like Neuralink. This expansion underscores its commitment to building a comprehensive platform from research to manufacturing.
The venture is co-founded by serial entrepreneur Dr. Phoenix Peng and Tianqiao Chen, founder of Shanda Group. Dr. Peng brings deep expertise from his doctoral work and previous BCI startups, providing strong technical leadership. Chen's involvement provides substantial strategic backing, positioning Gestala with a solid foundation for its ambitious long-term goals.
Pioneering Ultrasound-Based Neurotechnology
Gestala is moving beyond invasive electrode-based methods by focusing on functional ultrasound to observe brain activity. While electrodes excel at recording localized signals, ultrasound can monitor broader brain functions related to memory, emotion, and planning. This less invasive technique aims to capture the complex interactions between multiple brain regions.
The company's name, from Gestalt psychology, reflects its holistic philosophy that the whole is greater than the sum of its parts. Its objective is to develop a platform with comprehensive "read and write" capabilities across the brain. This vision involves decoding widespread neural activity while precisely modulating targeted deep neural circuits for therapeutic purposes.
The Convergence of Neuroscience and AI
Artificial intelligence is fundamental to translating Gestala's ultrasound data into meaningful insights. The company is developing a brain foundation model to analyze and unify diverse data streams, including cerebral blood flow and medical imaging. This AI-driven approach is crucial for decoding the brain's complex signals and overcoming technical challenges.
Co-founder Phoenix Peng envisions the company as a vital link between neuroscience and artificial intelligence. He believes that understanding the brain's natural intelligence is key to creating the next generation of AI. Through its work, Gestala aims to create a shared language that allows these two disciplines to advance together.
Navigating Future Clinical and Technical Hurdles
Gestala's initial clinical application will target chronic pain, with plans to later address conditions like depression and stroke rehabilitation. The company aims to unveil its first-generation BCI product and brain foundation model by the end of 2026. This timeline sets the stage for subsequent clinical trials and regulatory approval processes.
Despite its successful fundraising, the company faces significant technical and clinical hurdles. It must prove its system can consistently and safely produce reproducible results across different individuals in rigorous clinical trials. Furthermore, its AI model must demonstrate the ability to generalize across various tasks, individuals, and diseases.
With RMB 570 million in fresh capital and a clear strategic vision, Gestala is poised to become a formidable contender in the global BCI industry. The company's success now hinges on its ability to navigate the complex path from research to clinical reality. Its ultimate impact will be measured by its capacity to deliver tangible patient benefits and advance our understanding of the brain.